Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QT Guidance Reducing Number Of Drugs Leaving Early Development, Firms Say

Executive Summary

Stricter guidelines on QT prolongation are forcing manufacturers to drop compounds earlier in the development process, participants said during an FDA/Duke Cardiac Safety and Critical Path Initiative Think Tank meeting Oct. 11

You may also be interested in...

US FDA Plans To Standardize Review Of Blood Pressure Effects Of New Drugs

Approach is modeled after the interdisciplinary review team established more than a decade ago to review data on QT interval effects, FDA says; at a recent Duke meeting on assessing off-target pressor effects, discussion focused on lessons learned in the QT space that could be applied to studying blood pressure effects.

FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes

A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.

FDA/Duke Partnership Will Work On Cardiac Markers, Form Consortium

FDA's partnership with the Duke Clinical Research Institute to develop tools for identifying the potential cardiac effects of drugs and devices will examine gender differences as one of its first projects

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts